Barclays
OLMA icon

Barclays’s Olema Pharmaceuticals OLMA Stock Holding History

Barclays’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$262K Buy
30,324
+7,958
+36% +$86.7K ﹤0.01% 3811
2026
Q2 		$280K Buy
22,366
+8,368
+60% +$112K ﹤0.01% 3530
2026
Q1 		$209K Sell
13,998
-119,127
-89% -$2.65M ﹤0.01% 3664
2025
Q4 		$3.33M Buy
133,125
+28,501
+27% +$507K ﹤0.01% 2543
2025
Q3 		$1.02M Sell
104,624
-51,216
-33% -$308K ﹤0.01% 3353
2025
Q2 		$664K Buy
155,840
+2,736
+2% +$12.2K ﹤0.01% 3597
2025
Q1 		$576K Buy
153,104
+38,225
+33% +$192K ﹤0.01% 3442
2024
Q4 		$670K Buy
114,879
+19,964
+21% +$199K ﹤0.01% 3648
2024
Q3 		$1.13M Buy
94,915
+48,614
+105% +$621K ﹤0.01% 3279
2024
Q2 		$501K Buy
46,301
+3,491
+8% +$37.9K ﹤0.01% 3047
2024
Q1 		$485K Sell
42,810
-586
-1% -$7.56K ﹤0.01% 3615
2023
Q4 		$609K Buy
43,396
+38,739
+832% +$521K ﹤0.01% 3758
2023
Q3 		$57.5K Sell
4,657
-695
-13% -$7.08K ﹤0.01% 3810
2023
Q2 		$48.3K Buy
5,352
+730
+16% +$4.41K ﹤0.01% 3851
2023
Q1 		$16K Buy
4,622
+714
+18% +$2.91K ﹤0.01% 4691
2022
Q4 		$9.6K Sell
3,908
-1,669
-30% -$4.87K ﹤0.01% 4936
2022
Q3 		$16K Buy
5,577
+1,749
+46% +$7.42K ﹤0.01% 4139
2022
Q2 		$16K Sell
3,828
-4,212
-52% -$13.4K ﹤0.01% 4486
2022
Q1 		$34K Buy
+8,040
New +$44.3K ﹤0.01% 4259

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Barclays's OLMA Position: Q3 2026 in Review

Barclays increased its Olema Pharmaceuticals (OLMA) stake by 36% in Q3 2026, buying an estimated $86.7K and bringing the position to 30,324 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #3811.

Barclays first reported a position in OLMA in Q1 2022 and has held it in 19 quarters since. The position peaked at $3.33M in Q4 2025. 73 funds tracked by Wall St. Rank hold OLMA as of Q3 2026.

  • Barclays held 30,324 shares of Olema Pharmaceuticals worth $262K as of Q3 2026.
  • Barclays bought 7,958 Olema Pharmaceuticals shares in Q3 2026, an estimated $86.7K.
  • Olema Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3811 holding.
  • Barclays first reported a position in Olema Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Olema Pharmaceuticals position peaked at $3.33M in Q4 2025.
  • 73 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.